Sai Life Sciences Ltd

Sai Life Sciences Ltd

$SAILIFEPharmaceuticalsNSEBSE

Sai Life Sciences Ltd (SAILIFE) last traded at ₹1,457, a market capitalisation of ₹30,934 crore, on a P/E of 84.2. Over the past 52 weeks the stock has ranged between ₹784 and ₹1,490. Sai Life Sciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹554 crore and net profit of ₹73 crore. Sai Life Sciences Ltd’s annual general meeting is scheduled for 17 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Sai Life Sciences Ltd share price and key metrics

Current price
₹1,457
Market cap
₹30,934 cr
Stock P/E
84.2
Book value
₹117
ROE
15.4%
ROCE
19.6%
Dividend yield
0.00%
52w high / low
1490/784

Metrics as of 25 Aug 2026. Not real time.

Sai Life Sciences Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹554 cr, up 11.7% from ₹496 cr a year earlier. Net profit was ₹73 cr, up 21.7% year on year.

Sai Life Sciences Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales396440580496537556602554
Expenses293320422375392369426406
Operating profit102120158121146188177148
OPM %26%27%27%24%27%34%29%27%
Other income1091010150164
Interest2123111291088
Depreciation3634373840444546
Profit before tax55721198111213413998
Tax %25%25%26%25%25%25%25%25%
Net profit425488608410010473
EPS (₹)2.594.242.904.004.754.923.45

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Sai Life Sciences Ltd annual results

Sai Life Sciences Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7608701,2171,4651,6952,1922,250
Operating profit167126169287410631658
OPM %22%15%14%20%24%29%29%
Net profit6161083170349362
EPS (₹)8.1616.4817.12

TTM is the trailing twelve months to the most recent quarter.

Sai Life Sciences Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
24%
3 Years
22%
TTM
18%
Compounded Profit Growth
10 Years
%
5 Years
42%
3 Years
226%
TTM
51%
Stock Price CAGR
10 Years
%
5 Years
%
3 Years
%
1 Year
58%
Return on Equity
10 Years
%
5 Years
9%
3 Years
13%
Last Year
15%

Sai Life Sciences Ltd shareholding pattern

Promoters held 34.53% at Jun 2026, down from 35.15% at Jun 2025. FIIs 19.65% and DIIs 32.71%.

Sai Life Sciences Ltd shareholding pattern by quarter, in percent
% heldDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters35.23%35.16%35.15%34.95%34.70%34.61%34.53%
FIIs11.72%12.36%14.57%22.50%21.41%21.17%19.65%
DIIs11.95%13.26%21.64%29.92%31.41%31.54%32.71%
Public41.08%39.21%28.64%12.65%12.49%12.69%13.11%
No. of shareholders1,81,1221,40,6771,26,3801,19,7051,14,8201,17,5271,25,096

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Sai Life Sciences Ltd’s AGM?

Sai Life Sciences Ltd’s annual general meeting is scheduled for 17 Sept 2026.

  • AGM27th Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

Sai Life Sciences Ltd corporate filings

  • Weblink Letter To Shareholders - As Per Regulation 36(1)(B) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has issued a communication to shareholders in compliance with…

    Read the full analysis
  • Business Responsibility and Sustainability Report (BRSR) and ESG Databook of Sai Life Sciences Limited for the FY 2025-26Otherslow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has filed its Business Responsibility and Sustainability Report (BRSR)…

    Read the full analysis
  • Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-26Otherslow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has filed its Integrated Annual Report for the financial year 2025-26…

    Read the full analysis
  • Notice of 27th Annual General Meeting (AGM) of the CompanyAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited has issued a notice for its 27th Annual General Meeting (AGM)…

    Read the full analysis
  • Newspaper Publication relating to 27th AGM (Pre-dispatch Advt.)Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited has formally notified the stock exchanges of its 27th Annual…

    Read the full analysis
  • Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.AGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited has formally announced its 27th Annual General Meeting (AGM) to…

    Read the full analysis
  • Transcript of Earnings Conference Call organised on 07 August 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences reported Q1 FY27 revenue of INR 553 crore, a 12% YoY increase, with CRO…

    Read the full analysis
  • Newspaper publication for Un-audited Financial Results of the Company for the quarter ended on 30 June 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited has formally notified the stock exchanges regarding the…

    Read the full analysis
  • Monitoring Agency Report for the Quarter ended on 30 June 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has filed its Monitoring Agency Report for the quarter ended June 30…

    Read the full analysis
  • Recording of Earnings Call for the Unaudited Financial Results of the Company for the quarter ended on 30 June 2026.Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited has formally filed the audio recording of its earnings…

    Read the full analysis
  • Investor Presentation for the quarter ended on 30 June 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited delivered a steady performance in Q1 FY27 with revenue from…

    Read the full analysis
  • Allotment of 18,700 equity shares under Employee Stock Option PlanCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has announced the allotment of 18,700 equity shares to employees under…

    Read the full analysis
  • Press Release for the Unaudited financial results for the quarter ended 30 June 2026Company Updatehigh impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited delivered a solid performance for the quarter ended 30 June…

    Read the full analysis
  • Board Meeting Outcome for Approval of Unaudited Financial Results (Standalone and Consolidated) For the Quarter Ended On 30 June 2026Board Meetingmedium impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences Limited reported consolidated revenue from operations of 554.29 crore…

    Read the full analysis
  • Analyst/Investor Meet on 13 August 2026 and 14 August 2026 at SingaporeCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Sai Life Sciences has announced a series of analyst and investor meetings to be held in…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Sai Life Sciences Ltd

Cruxal reads every Sai Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.